Anant Labs

Sunitinib

CAS 557795-19-4

Overview

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor that was approved by the FDA for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor on January 26, 2006

Anant Labs manufacture and furnish high quality Sunitinib impurities for global markets. Our Sunitinib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.

Sunitinib
In Stock

Sunitinib

CAS 557795-19-4In Stock
WhatsApp
Technical Data
CAS557795-19-4
Mol. FormulaC22H27FN4O2
Mol. Weight398.482 g/mol
IUPACN-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
SMILESCCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C
InChIInChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
InChI KeyWINHZLLDWRZWRT-ATVHPVEESA-N

Note: We are upgrading our system, Cat No will change.

Synonyms
Sunitinib557795-19-4SU-11248SU11248sunitinibumSu-011248NSC-750690N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamideSU011248N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

Looking for a specific reference standard?

Tell us what you need. Our team responds within one business day.